• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia - 30 Studies Found

Completed : Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
: Chronic Myelomonocytic Leukemia
: 2010-04-01
: Drug: Decitabine 20mg/m2/day, one hour intravenous infusion, every day during 5 days
Active, not recruiting : Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia
: Chronic Myelomonocytic Leukemia
: 2010-12-01
: Drug: Decitabine Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once
Completed : A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
: Chronic Myelomonocytic Leukemia
: 2011-04-29
: Drug: 5-Azacitidine Administered on Days 1-7 of each Cycle
Completed : Lenalidomide in Patients With Chronic Myelomonocytic Leukemia
: Chronic Myelomonocytic Leukemia
: 2011-05-09
: Drug: Revlimid Dose escalation 5mg - 10mg - 15mg - 20mg in
Recruiting : The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
: Chronic Myelomonocytic Leukemia
: 2009-11-06
Completed : Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
: Chronic Myelomonocytic Leukemia (CMML)
: 2015-08-27
: Drug: lenzilumab Other Names:
  • KB003
  • Monoclonal Antibody

Completed : Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia
: Leukemia, Myelomonocytic, Chronic
: 2016-06-15
: Drug: Tipifarnib Oral tablet Other Names:
Completed : A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)
: Leukemia, Myelomonocytic, Chronic
: 2017-01-24
:
  • Drug: Cohort 1, Ceplene® and Proleukin®

Completed : Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
:
  • Chronic Myelomonocytic Leukemia
  • Chronic Myelogenous Leukemia : 2004-03-08
    : Drug: Imatinib
Terminated : Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)
:
  • Acute Myelogenous Leukemia
  • Chronic Myelomonocytic Leukemia

  • : 2003-12-19
    : Drug: DTGM Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.